We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.91B
1-Year Est. Return 44.39%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+44.39%
3 Year Est. Return
+110.36%
5 Year Est. Return
+52.4%
10 Year Est. Return
+1,142.23%
AUM
$483M
AUM Growth
-$111M
Cap. Flow
-$58.5M
Cap. Flow %
-12.12%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$17.6M
2
STAA icon
STAAR Surgical
STAA
+$12M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$4.84M
4
IMPR
IMPRIVATA, INC COM
IMPR
+$792K

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$82.9M
2
LCTX icon
Lineage Cell Therapeutics
LCTX
+$3.92M

Sector Composition

Rank Sector Weight
1 Healthcare 44.25%
2 Consumer Staples 44.19%
3 Miscellaneous 9.63%
4 Technology 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$87.5B
$213M 44.19%
19,189,632
– –
STAA icon
2
STAAR Surgical
STAA
$1.14B
$77M 15.95%
10,417,670
+1,770,747
+20% +$12M
LCTX icon
3
Lineage Cell Therapeutics
LCTX
$263M
$63.6M 13.18%
25,333,905
-1,756,344
-6% -$3.92M
IWM icon
4
iShares Russell 2000 ETF
IWM
$76.1B
$46.5M 9.63%
420,000
+170,000
+68% +$17.6M
CYNO
5
DELISTED
Cynosure, Inc. Class A
CYNO
$40.5M 8.38%
916,975
– –
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$19.8M 4.09%
322,411
-1,297,557
-80% -$82.9M
IMPR
7
DELISTED
IMPRIVATA, INC COM
IMPR
$9.32M 1.93%
737,911
+69,385
+10% +$792K
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$7.71M 1.6%
1,641,025
– –
IMDX
9
Insight Molecular Diagnostics
IMDX
$118M
$5.04M 1.04%
+54,661
New +$4.84M

Similar funds

EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.91B AUM 19.99% 1-Year Est. Return
RMA
Roffman Miller Associates Philadelphia, Pennsylvania $1.91B AUM 28.29% 1-Year Est. Return
LWMT
Legacy Wealth Management (Tennessee) Memphis, Tennessee $1.91B AUM 17.42% 1-Year Est. Return
FIB
First Interstate Bank Billings, Montana $1.92B AUM 19.65% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $1.92B AUM 6.41% 1-Year Est. Return
HPC
Hill Path Capital New York $1.92B AUM 5.67% 1-Year Est. Return
R
Rebalance Palo Alto, California $1.91B AUM 16.23% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

Broadwood Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadwood Capital held 10 positions worth $483M, down 19% from $594M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital withdrew a net $58.5M in Q1 2016, closing 1 position and reducing 2 holdings. Its largest reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $82.9M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier, followed by Consumer Staples and Miscellaneous.

Against the trend, Broadwood Capital opened a new position in Insight Molecular Diagnostics worth $5.04M.

  • Broadwood Capital's largest Q1 2016 buy was Insight Molecular Diagnostics: 54,661 shares worth $5.04M.
  • Broadwood Capital added most to iShares Russell 2000 ETF in Q1 2016, an estimated $17.6M increase.
  • Broadwood Capital's biggest Q1 2016 reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $82.9M.
  • Broadwood Capital's ten largest holdings make up 100% of its $483M portfolio in Q1 2016.
  • Broadwood Capital opened 1 new position and closed 1 in Q1 2016.
  • Broadwood Capital's portfolio value fell 19% quarter-over-quarter to $483M.

Based on Broadwood Capital's 13F filing for Q1 2016, filed 16 May 2016.